GC Biopharma Expands Capabilities with CMO Rights
GC Biopharma, a prominent biopharmaceutical company based in South Korea, has announced that it has reached a vital agreement with Curevo Vaccine to obtain contract manufacturing (CMO) rights for amezosvatein, a new recombinant shingles vaccine currently undergoing clinical development.
This collaboration will see GC Biopharma taking on the responsibility for producing part of the commercial supply of amezosvatein, enabling it to play a significant role in the global market for this important vaccine.
The Growing Shingles Vaccine Market
The shingles vaccine market is rapidly evolving, with the current leader being GSK's Shingrix. Since its entry into the market in 2018, Shingrix has expanded its reach impressively, growing at a rate of approximately 20% annually. From a market size of KRW 1 trillion in 2017, it is expected to reach around KRW 6 trillion (approximately USD 4.4 billion) by 2024. GSK reported global sales exceeding KRW 5 trillion for Shingrix last year, commanding a market share of more than 90%.
Amezosvatein: A New Player in the Market
Amezosvatein is designed as an adjuvanted recombinant protein vaccine. It aims to rival Shingrix by utilizing a synthetic adjuvant to mitigate common vaccine side effects such as local injection-site pain and systemic reactions similar to flu-like symptoms. This unique formulation aims to ensure that patients have a more comfortable vaccination experience.
Clinical trials for amezosvatein have shown promising results. Early Phase 2 trials demonstrated that the vaccine exhibited non-inferior immune response compared to Shingrix while showing favorable tolerability. Curevo Vaccine is currently advancing with an expanded Phase 2 study involving 640 participants aged 50 and older. The anticipated timeline for completing this trial is set for 2026, after which they plan to move into Phase 3 studies and lay the groundwork for global commercialization.
Implications for Patients and Healthcare Providers
The introduction of amezosvatein is expected to provide healthcare providers and patients with an additional alternative, which is particularly important in a segment currently dominated by just one product. This diversification within the shifts offered in the shingles vaccination landscape could greatly benefit patient choice and overall public health outcomes.
Strategic Growth for GC Biopharma
Commenting on the agreement, Huh Eun-Chul, the CEO of GC Biopharma, emphasized its significance. He stated, "This agreement marks a critical milestone in securing long-term growth drivers for GC Biopharma. We will continue to expand our global vaccine business through strategic collaborations and differentiated technologies." The company's strategy clearly hinges on innovation and collaboration as key elements to driving future success.
About GC Biopharma
GC Biopharma, previously known as Green Cross Corporation, is a well-established biopharmaceutical entity headquartered in Yong-in, South Korea. With over fifty years of experience, the company specializes in the development and production of plasma derivatives and vaccines. It has made strides in expanding its global footprint, highlighted by the successful US market entry of Alyglo, an intravenous immunoglobulin G product in 2024.
GC Biopharma is dedicated to meeting the future healthcare needs by harnessing cutting-edge research and development capabilities focused on protein engineering, mRNA technologies, and lipid nanoparticle drug delivery systems. Its mission encompasses a commitment to creating therapeutics for rare diseases as well as immunology and inflammation conditions.
Frequently Asked Questions
What type of vaccine is amezosvatein?
Amezosvatein is a recombinant shingles vaccine designed to offer an alternative to existing products like Shingrix.
Who are GC Biopharma's partners in this development?
GC Biopharma has partnered with Curevo Vaccine to secure CMO rights for amezosvatein.
What are the main advantages of amezosvatein?
The vaccine aims to reduce common side effects associated with vaccinations while maintaining a strong immune response comparable to leading competitors.
When is amezosvatein expected to enter the market?
After completing Phase 2 studies in 2026, GC Biopharma aims to proceed to Phase 3 trials toward global commercialization.
How does GC Biopharma plan to grow its business?
The company aims to expand through strategic collaborations and innovative vaccine technologies to enhance its portfolio and market presence.
